Glaukos Corp GKOS
We take great care to ensure that the data presented and summarized in this overview for GLAUKOS Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GKOS
View all-
Black Rock Inc. New York, NY8.04MShares$724 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.05MShares$544 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA3.58MShares$322 Million0.05% of portfolio
-
Primecap Management CO Pasadena, CA2.25MShares$203 Million0.15% of portfolio
-
State Street Corp Boston, MA2.1MShares$189 Million0.01% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN1.9MShares$171 Million0.04% of portfolio
-
Alliancebernstein L.P. New York, NY1.73MShares$156 Million0.05% of portfolio
-
Geode Capital Management, LLC Boston, MA1.32MShares$118 Million0.01% of portfolio
-
Westfield Capital Management CO LP Boston, MA1.23MShares$111 Million0.46% of portfolio
-
William Blair Investment Management, LLC Chicago, IL1.09MShares$98.5 Million0.25% of portfolio
Latest Institutional Activity in GKOS
Top Purchases
Top Sells
About GKOS
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Insider Transactions at GKOS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 25
2025
|
Alex R. Thurman SVP & CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
315
-0.62%
|
$33,075
$105.0 P/Share
|
|
Nov 18
2025
|
Joseph E Gilliam PRESIDENT & COO |
SELL
Open market or private sale
|
Direct |
19,340
-17.31%
|
$1,740,600
$90.0 P/Share
|
|
Sep 23
2025
|
Thomas William Burns CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,059
-2.62%
|
$340,956
$84.69 P/Share
|
|
Sep 23
2025
|
Tomas Navratil CHIEF DEVELOPMENT OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
483
-0.63%
|
$40,572
$84.69 P/Share
|
|
Sep 23
2025
|
Joseph E Gilliam PRESIDENT & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,056
-0.94%
|
$88,704
$84.69 P/Share
|
|
Sep 22
2025
|
Tomas Navratil CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
517
-0.22%
|
$42,911
$83.75 P/Share
|
|
Sep 19
2025
|
Thomas William Burns CHAIRMAN & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,098
-0.7%
|
$91,134
$83.47 P/Share
|
|
Sep 19
2025
|
Tomas Navratil CHIEF DEVELOPMENT OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
510
-0.66%
|
$42,330
$83.47 P/Share
|
|
Sep 18
2025
|
Thomas William Burns CHAIRMAN & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
15,417
+9.0%
|
-
|
|
Sep 18
2025
|
Joseph E Gilliam PRESIDENT & COO |
BUY
Grant, award, or other acquisition
|
Direct |
3,884
+3.33%
|
-
|
|
Sep 18
2025
|
Tomas Navratil CHIEF DEVELOPMENT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,948
+2.45%
|
-
|
|
Sep 11
2025
|
Tomas Navratil CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
5,142
-3.24%
|
$452,496
$88.3 P/Share
|
|
Jun 11
2025
|
David F Hoffmeister |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+43.92%
|
$800,000
$32.0 P/Share
|
|
May 29
2025
|
Leana Wen |
BUY
Grant, award, or other acquisition
|
Direct |
2,108
+9.2%
|
-
|
|
May 29
2025
|
Gilbert H Kliman |
BUY
Grant, award, or other acquisition
|
Direct |
2,108
+5.7%
|
-
|
|
May 29
2025
|
Denice Torres |
BUY
Grant, award, or other acquisition
|
Direct |
2,108
+8.85%
|
-
|
|
May 29
2025
|
Aimee S Weisner |
BUY
Grant, award, or other acquisition
|
Direct |
2,108
+9.91%
|
-
|
|
May 29
2025
|
Marc Stapley |
BUY
Grant, award, or other acquisition
|
Direct |
2,108
+5.43%
|
-
|
|
May 29
2025
|
David F Hoffmeister |
BUY
Grant, award, or other acquisition
|
Direct |
2,108
+23.35%
|
-
|
|
May 29
2025
|
Mark J Foley |
BUY
Grant, award, or other acquisition
|
Direct |
2,108
+3.55%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 185K shares |
|---|---|
| Exercise of conversion of derivative security | 80.3K shares |
| Open market or private sale | 66.3K shares |
|---|---|
| Payment of exercise price or tax liability | 84.4K shares |